A clinical study of pemphigus vulgaris and its variants, evaluation of safety and efficacy of glucocorticoids versus immunosuppressants at tertiary care hospital: a study of 75 cases

Kiran Chotaliya; Darshil Shailesh Kantaria; Raksha Patel; Krishna Desai

doi:10.18203/issn.2455-4529.IntJResDermatol20252547

Authors

Kiran Chotaliya Hairfree and Hairgrow Clinic, Pune, Maharashtra, India
Darshil Shailesh Kantaria Department of Dermatology, GMERS Medical College and hospital, Gotri, Vadodara, Gujarat, India
Raksha Patel Department of Dermatology, GMERS Medical College and hospital, Gotri, Vadodara, Gujarat, India
Krishna Desai Department of Dermatology, GMERS Medical College and hospital, Gotri, Vadodara, Gujarat, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20252547

Keywords:

Pemphigus, Glucocorticoids, Cyclophosphamide, Other immunosuppressants

Abstract

Background: Pemphigus is an autoimmune blistering disorder affecting skin and mucous membranes. Autoantibodies target desmoglein proteins, leading to acantholysis. Glucocorticoids (GCs) are the primary treatment, but long-term use leads to side effects, prompting the use of other immunosuppressants like cyclophosphamide, rituximab, azathioprine, methotraxate for steroid-sparing effects.

Methods: Seventy-five pemphigus patients were included. Diagnoses were based on clinical and histopathological findings. Patients were treated with GCs alone or in combination with immunosuppressants like cyclophosphamide, rituximab, azathioprine, methotraxate. Clinical remission and adverse events recorded over an 18-month follow-up.

Results: The 46 patients were treated with GCs alone, while 19 received additional cyclophosphamide. 89.5% of patients treated with GCs and cyclophosphamide achieved remission within 4 months, compared to 73.9% with GCs alone.

Conclusions: Cyclophosphamide and other immunosuppressants enhances clinical outcomes by achieving earlier remission and reducing relapse rates in pemphigus patients compared to GCs alone. Its use as an adjunct may offer significant steroid-sparing effects.

Metrics

Metrics Loading ...

References

Neil Korman, Cleveland O H. Pemphigus. J. Am. Acad. Dermatol. 1988;18(6):1219-38. DOI: https://doi.org/10.1016/S0190-9622(88)70128-0

Lapidoth M, David M, Ben-Amitai D, Katzenelson V, Lustig S, Sandbank M. The efficacy of combine treatment with prednisolon and cyclophosphamide in patient with Pemphigus. J Am Acad Dermatol. 1994;30(5pt1):752-7. DOI: https://doi.org/10.1016/S0190-9622(08)81506-X

Kar PK, Murthy PS, Rajagopal R. Management of pemphigus vulgaris during acute phase. Indian J Dermatol Venereol Leprol. 2003;69(2):109-13.

Muller S, StonelyJR. Pemphigus vulgaris and pemphigus foliaceus. In: Wonarowska F. Briggaman R. eds. Management of blistering disease, London, Chapman and Hall. 1990;43-61. DOI: https://doi.org/10.1007/978-1-4899-7190-6_4

Arya SR, Valand AG, Krishna K. A clinico-pathological study of 70 cases of pemphigus. Ind J Derm Ven Lep. 1999;65(4):169-71.

Fleischi ME, Rachel HV, Pandya AG. Pulse cyclophosphamide therapy in pemphigus. Arch Dermatol. 1999;135(1):57-61.

Mccune J, Globus J, Zendes W, Bohlke P, Dunne R, Fox DA. Clinical and immunological effects of monthly administration of intravenous cyclophosphamide in severe lupus erythematosus. N Engl J Med. 1990;318(22):1423-31. DOI: https://doi.org/10.1056/NEJM198806023182203

Pandya AG, Sontheimer RD. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol. 1992;128(12):1626-30.

Baker GL, Kalil LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA. Malignancy following treatment of rheumatoid arthritis following cyclophosphamide. Am J Med. 1987;83(1):1-19. DOI: https://doi.org/10.1016/0002-9343(87)90490-6

Pasricha JS, Srivastava G. Cure in pemphigus a possibility. Indian J Dermatol Venereol Leprol. 1986;52:185-6.

Pasricha JS, Gupta R. Pulse therapy with dexamethasone-cyclophosphamide in pemphigus. Indian J Dermatol Venereol Leprol. 1984;50(5):199-203.

Sethy PK, Khandpur S, Sharma VK. Randomized open comparative trial of dexamethasone-cyclophosphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral prednisolone in pemphigus vulgaris. Indian J Dermatol Venereol Leprol. 2009;75(5):476-82. DOI: https://doi.org/10.4103/0378-6323.55390

Pasricha JS, Khaitan BK, Raman RS, Chandra M. Dexamethasone cyclophosphamide pulse therapy for pemphigus. Int J Dermatol. 1995;34(12):875-82. DOI: https://doi.org/10.1111/j.1365-4362.1995.tb04430.x

Pasricha JS, Das SS. Curative effect of dexamethasone-cyclophosphamide pulse therapy for the treatment of pemphigus vulgaris. Int J Dermatol. 1992;31(12):875-7. DOI: https://doi.org/10.1111/j.1365-4362.1992.tb03549.x

Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol. 1990;29(5):371-4. DOI: https://doi.org/10.1111/j.1365-4362.1990.tb04767.x

Masood Q, Hassan I, Majid I, Khan D, Manzooi S, Qayoom S, et al. Dexamethasone cyclophosphamide pulse therapy in pemphigus: experience in Kashmir valley. Indian J Dermatol Venereol Leprol. 2003;69(2):97-9.

Kanwar AJ, Kaur S, Thami GP. Long-term efficacy of dexamethasone-cyclophosphamide pulse therapy in pemphigus. Dermatology. 2002;204(3):228-31. DOI: https://doi.org/10.1159/000057886

Pandya AG, Sontheimer RD. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol. 1992;128(12):1626-30. DOI: https://doi.org/10.1001/archderm.1992.04530010064010

Fleischli ME, Valek RH, Pandya AG. Pulse intravenous cyclophosphamide therapy in pemphigus. Arch Dermatol. 1999;135(1):57-61. DOI: https://doi.org/10.1001/archderm.135.1.57